All In Biotech

Drug Trial Radar · NCT00652080

An Open-Label Safety Study of API 31510 in a Topical Cream for in Situ Cutaneous Squamous Cell Carcinoma (SCCIS)

Last checked: Nov 19, 2026Latest source record: Mar 5, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

35

Actual

Start

Jun 2008

Primary completion

Jan 2010

Study completion Jan 2010

Sponsor

Lead sponsor
BPGbioIndustry
Sponsor type
Industry
First posted
Apr 3, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety and tolerability of pharmaceutical compound 31510 in a topical cream when applied to in situ cutaneous squamous cell carcinoma and to obtain preliminary efficacy data for the treatment of in situ cutaneous squamous cell carcinoma by Compound 31510 topical cream.

Conditions

  • Squamous Cell Carcinoma

Interventions

  • API 31510Drug

    Topical Cream; 3% active; AM \& PM application

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse EventsTime frame: 6 weeks

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Burke Pharmaceuticals

    Hot Springs, Arkansas

  • Skin Surgery Medical Group, Inc.

    San Diego, California

  • Glazer Dermatology

    Buffalo Grove, Illinois

  • Long Island Skin Cancer and Dermatalogic Surgery, PC

    Smithtown, New York

  • Education and Research Foundation

    Lynchburg, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.